Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Catheter-Directed Thrombolysis Device Type and Dosing on Treatment Outcomes in Intermediate-Risk Pulmonary Embolism: A PEERLESS Randomized Controlled Trial Post Hoc Analysis.

Journal of vascular and interventional radiology : JVIR·2025
Same author

Percutaneous Hepatic Perfusion Melphalan Induced Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease) in a Patient with Metastatic Uveal Melanoma.

Case reports in oncology·2025
Same author

Response by Jaber et al to Letter Regarding Article, "Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial".

Circulation·2025
Same author

Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same author

The Evolving Application of Radiation Segmentectomy for the Treatment of Hepatic Malignancy.

Radiology·2025
Same author

Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.

Hepatology (Baltimore, Md.)·2025

Related Experiment Video

Updated: Jul 3, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Chemoembolization of hepatic malignancy.

Carin F Gonsalves1, Daniel B Brown

  • 1Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.

Abdominal Imaging
|August 1, 2008
PubMed
Summary
This summary is machine-generated.

Transarterial chemoembolization is a key treatment for liver cancers. This review covers patient selection, technique, outcomes, and complications of this interventional oncology procedure.

More Related Videos

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jul 3, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Area of Science:

  • Interventional Oncology
  • Hepatobiliary Malignancies
  • Vascular Interventions

Background:

  • Transarterial chemoembolization (TACE) is a cornerstone therapy for unresectable primary and secondary liver tumors.
  • It involves delivering chemotherapy and embolic agents directly to the tumor vasculature.
  • TACE plays a critical role in the multidisciplinary management of hepatic malignancies.

Purpose of the Study:

  • To provide a comprehensive overview of transarterial chemoembolization for hepatic malignancies.
  • To discuss critical aspects including patient selection, procedural techniques, and outcomes.
  • To highlight potential complications and management strategies associated with TACE.

Main Methods:

  • Review of current literature and clinical practices regarding TACE for liver cancer.
  • Discussion of imaging guidance and embolic material selection.
  • Analysis of patient selection criteria based on tumor characteristics and liver function.

Main Results:

  • TACE demonstrates efficacy in controlling tumor burden and improving survival in select patients.
  • Procedure success rates are high, but outcomes vary based on tumor type and extent.
  • Complications can occur, ranging from post-embolization syndrome to hepatic ischemia.

Conclusions:

  • Transarterial chemoembolization is an effective treatment modality for selected patients with primary and secondary hepatic malignancies.
  • Careful patient selection and meticulous technique are paramount for optimizing outcomes and minimizing risks.
  • Understanding and managing potential complications are essential for successful TACE therapy.